Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives - PubMed (original) (raw)

Review

Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives

Chrysi Koliaki et al. Curr Obes Rep. 2019 Dec.

Abstract

Purpose of review: This review provides a comprehensive update on the definition, assessment, epidemiology, pathophysiology, clinical implications, and therapeutic approach of sarcopenic obesity (SO) and highlights the challenges, limitations, and knowledge gaps in SO research.

Recent findings: The confluence of a rapidly aging population with rising obesity rates has led to the phenotype of SO, defined as the concurrent presence of sarcopenia and obesity. Despite efforts, a standardized definition of SO is still lacking. Its prevalence varies widely between studies, depending on population characteristics and different definitions. The major pathogenetic mechanisms include age-related changes in body composition and hormonal milieu, positive energy balance, pro-inflammatory pathways, and insulin resistance. Lifestyle interventions, including caloric restriction and physical activity, are the cornerstones of SO treatment. SO is a multifaceted syndrome with serious clinical implications. The development and implementation of effective prevention and treatment strategies is a top priority based on its dramatically increasing health impact.

Keywords: Aging; Body composition; Obesity; Sarcopenia; Sarcopenic obesity; Skeletal muscle tissue.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2212-7 - PubMed
    1. Age Ageing. 2011 Jul;40(4):423-9 - PubMed
    1. J Frailty Aging. 2018;7(1):2-9 - PubMed
    1. Medicine (Baltimore). 2017 Jun;96(23):e7115 - PubMed
    1. Int J Clin Pract. 2015 Oct;69(10):1032-49 - PubMed

Publication types

MeSH terms

LinkOut - more resources